TNFRSF9 and cancer: Triple combinations of anti-PD-L1 antibodies and TTmAbs (against RTKs, and anti-CD20 and anti-CD79b antibody-drug conjugates), or ICM inhibitors (anti-CD137, anti-CTLA-4 antibodies) also have been assessed for cancer management, as well as the anti-PD1/TIGIT/PVRIG and anti-PD1/CD40/CFS1 combinations.